
Stephen A. Vu
Examiner (ID: 5350, Phone: (571)272-1961 , Office: P/3652 )
| Most Active Art Unit | 3652 |
| Art Unit(s) | 3652, 3651, 3624, 3636, 3507, 3654 |
| Total Applications | 2060 |
| Issued Applications | 1660 |
| Pending Applications | 109 |
| Abandoned Applications | 310 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18102422
[patent_doc_number] => 11542297
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Compositions and methods for treating CNS disorders
[patent_app_type] => utility
[patent_app_number] => 17/695033
[patent_app_country] => US
[patent_app_date] => 2022-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54618
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17695033
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/695033 | Compositions and methods for treating CNS disorders | Mar 14, 2022 | Issued |
Array
(
[id] => 19871293
[patent_doc_number] => 12264137
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-01
[patent_title] => 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/691186
[patent_app_country] => US
[patent_app_date] => 2022-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18783
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 782
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17691186
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/691186 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Mar 9, 2022 | Issued |
Array
(
[id] => 19012953
[patent_doc_number] => 11919868
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-05
[patent_title] => Heterocyclic compounds and related methods
[patent_app_type] => utility
[patent_app_number] => 17/684352
[patent_app_country] => US
[patent_app_date] => 2022-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28453
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684352
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/684352 | Heterocyclic compounds and related methods | Feb 28, 2022 | Issued |
Array
(
[id] => 18093055
[patent_doc_number] => 20220411396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => TRIOXOLANE AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/680825
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63872
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680825
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/680825 | Trioxolane agents | Feb 24, 2022 | Issued |
Array
(
[id] => 19233711
[patent_doc_number] => 20240190903
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/277204
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47750
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277204
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/277204 | COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE | Feb 24, 2022 | Pending |
Array
(
[id] => 19209862
[patent_doc_number] => 11998901
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Metal complex, method for producing same, and method for producing gamma-lactam compound using same
[patent_app_type] => utility
[patent_app_number] => 17/676078
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21071
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17676078
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/676078 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | Feb 17, 2022 | Issued |
Array
(
[id] => 17828305
[patent_doc_number] => 20220265609
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION
[patent_app_type] => utility
[patent_app_number] => 17/665347
[patent_app_country] => US
[patent_app_date] => 2022-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19751
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17665347
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/665347 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | Feb 3, 2022 | Abandoned |
Array
(
[id] => 18435967
[patent_doc_number] => 20230183261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => Macrocyclic MCL-1 Inhibitors and Methods of Use
[patent_app_type] => utility
[patent_app_number] => 17/649906
[patent_app_country] => US
[patent_app_date] => 2022-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61454
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 1247
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17649906
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/649906 | Macrocyclic MCL-1 Inhibitors and Methods of Use | Feb 2, 2022 | Abandoned |
Array
(
[id] => 19187685
[patent_doc_number] => 20240166598
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/264109
[patent_app_country] => US
[patent_app_date] => 2022-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44278
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 215
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264109
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/264109 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME | Feb 1, 2022 | Pending |
Array
(
[id] => 18084319
[patent_doc_number] => 11534426
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-12-27
[patent_title] => Use of ergothioneine for extending lifespan or improving healthspan
[patent_app_type] => utility
[patent_app_number] => 17/585455
[patent_app_country] => US
[patent_app_date] => 2022-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 18
[patent_no_of_words] => 12636
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17585455
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/585455 | Use of ergothioneine for extending lifespan or improving healthspan | Jan 25, 2022 | Issued |
Array
(
[id] => 17593456
[patent_doc_number] => 20220143029
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/585493
[patent_app_country] => US
[patent_app_date] => 2022-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15256
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17585493
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/585493 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES | Jan 25, 2022 | Abandoned |
Array
(
[id] => 17595206
[patent_doc_number] => 20220144779
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => LAPPACONITINE DERIVATIVE WITH ANALGESIC ACTIVITY, AND PREPARATION AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/581920
[patent_app_country] => US
[patent_app_date] => 2022-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 402
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17581920
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/581920 | Lappaconitine derivative with analgesic activity, and preparation and application thereof | Jan 21, 2022 | Issued |
Array
(
[id] => 19032406
[patent_doc_number] => 20240082221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF COMPOUNDS THAT PROTECT AGAINST LIPOFUSCIN CYTOTOXICITY
[patent_app_type] => utility
[patent_app_number] => 18/273678
[patent_app_country] => US
[patent_app_date] => 2022-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25292
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273678
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/273678 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF COMPOUNDS THAT PROTECT AGAINST LIPOFUSCIN CYTOTOXICITY | Jan 20, 2022 | Pending |
Array
(
[id] => 17775074
[patent_doc_number] => 20220241423
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/575481
[patent_app_country] => US
[patent_app_date] => 2022-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59711
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17575481
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/575481 | Camptothecine antibody-drug conjugates and methods of use thereof | Jan 12, 2022 | Issued |
Array
(
[id] => 18012109
[patent_doc_number] => 11504383
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-22
[patent_title] => Crystalline forms of a Ryanodine receptor modulator and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/571038
[patent_app_country] => US
[patent_app_date] => 2022-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 14
[patent_no_of_words] => 18213
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571038
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/571038 | Crystalline forms of a Ryanodine receptor modulator and uses thereof | Jan 6, 2022 | Issued |
Array
(
[id] => 17974304
[patent_doc_number] => 11491141
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-11-08
[patent_title] => Methods of treating glutathione deficiencies and deficiencies in glutathione synthetase activity
[patent_app_type] => utility
[patent_app_number] => 17/569563
[patent_app_country] => US
[patent_app_date] => 2022-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 6357
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17569563
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/569563 | Methods of treating glutathione deficiencies and deficiencies in glutathione synthetase activity | Jan 5, 2022 | Issued |
Array
(
[id] => 19201368
[patent_doc_number] => 20240173267
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/276527
[patent_app_country] => US
[patent_app_date] => 2022-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70641
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -169
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18276527
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/276527 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Jan 5, 2022 | Pending |
Array
(
[id] => 19543121
[patent_doc_number] => 20240360157
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => TYK2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/260275
[patent_app_country] => US
[patent_app_date] => 2022-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44162
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 362
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260275
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/260275 | TYK2 INHIBITORS | Jan 5, 2022 | Pending |
Array
(
[id] => 19325966
[patent_doc_number] => 12043631
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-23
[patent_title] => BACE1 inhibitors for the treatment of Alzheimer's disease
[patent_app_type] => utility
[patent_app_number] => 17/567737
[patent_app_country] => US
[patent_app_date] => 2022-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5661
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17567737
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/567737 | BACE1 inhibitors for the treatment of Alzheimer's disease | Jan 2, 2022 | Issued |
Array
(
[id] => 17720361
[patent_doc_number] => 20220213081
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/566915
[patent_app_country] => US
[patent_app_date] => 2021-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45903
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17566915
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/566915 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | Dec 30, 2021 | Abandoned |